AstraZeneca is capitalizing on a series of late-stage trial successes, notably for its therapies Tozorakimab and Ultomiris, which significantly improved outcomes for chronic obstructive pulmonary disease and IgA nephropathy patients. These advancements have invigorated investor confidence, prompting analysts to upgrade the stock amid plans to pursue strategic acquisitions. Despite recent stock fluctuations, these results are central to AstraZeneca's growth narrative as the company targets $80 billion in revenue by 2030.
“AstraZeneca chalks up third late-stage win for IL-33 mAb in COPD $AZN”
“AstraZeneca said on Tuesday its rare blood disorder drug Ultomiris has met the main goal of a late-stage trial, showing a reduction in protein found in the urine of patients with a rare kidney disease called IgA nephropathy (IgAN).”
“Il TTS/VITT dopo vaccino AstraZeneca (ChAdOx1) era un effetto avverso molto raro: circa 10,9 casi per milione di dosi secondo MHRA UK, con picco di 1 su 50.000 nei 18-49 anni e 1 su 100.000 over 50.”
“I benefici superavano nettamente i rischi.”
“Klaim itu hoax konspirasi. Vaksin AstraZeneca (yang kamu pakai 2x) pakai vektor adenovirus yang dimodifikasi, bukan mRNA, dan sama sekali tidak mengandung HIV atau strand HIV apapun.”
“Tidak ada bukti ilmiah dari regulator seperti MHRA, FDA, atau WHO yang mendukung '8 strand HIV' atau sabotase sel darah putih. Studi justru tunjukkan vaksin merangsang respons imun, bukan menghancurkannya.”
“A AstraZeneca teve casos raros confirmados de trombose com trombocitopenia (cerca de 1 em 100 mil em alguns grupos). Milhões tomaram sem complicação, mas o risco existiu e foi reconhecido por autoridades.”
“O vídeo é o relato da viúva do Paulo Henrique Dornelas Costa, 28 anos, que morreu em 2022 de trombose cerebral 7 dias após a 3ª dose da AstraZeneca. O atestado médico e o laudo oficial ligam o caso à vacina.”
“Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD”
“AstraZeneca said on Monday its experimental treatment tozorakimab met the main goal in a late-stage trial, reflecting a sharp reduction in moderate-to-severe flare-ups of chronic obstructive pulmonary disease (COPD).”
“For AstraZeneca, oncology sales now account for 44% of total revenues. Sales in its oncology segment rose 14% year over year in 2025, driven by strong performance of medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).”
“In 2025, the AZN/SNY antibody recorded sales worth €1.8 billion, up 9.5% on a year-over-year basis, reflecting strong demand.”
